GlassScriptPhysician profile
Thomas F Jan
NPI 1871685404
$21,739.61
in general payments reported to CMS, 2019-2025
20 companies · $89.59 in 2025
The $89.59 reported for 2025 was less than what a typical Pain Medicine (Physical Medicine & Rehabilitation) provider received nationally (typical 2025 total: $400).
See the full distribution for Pain Medicine (Physical Medicine & Rehabilitation)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20K · 2020: $428 · 2021: $225 · 2022: $384 · 2023: $405 · 2024: $89.35 · 2025: $89.59.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $583.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $583.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mdd US Operations, LLC | $14,526.93 | 2019-2020 | |
| Indivior INC. | $5,291.94 | 2019-2024 | Sublocade |
| Collegium Pharmaceutical, INC. | $441.14 | 2019-2023 | Xtampza |
| Alkermes, INC. | $378.82 | 2019-2023 | Vivitrol |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $265.50 | 2019-2022 | |
| Abbvie INC. | $174.87 | 2022-2024 | |
| Averitas Pharma INC. | $120.13 | 2023 | Qutenza |
| Depuy Synthes Sales INC. | $85.74 | 2020-2023 | Orthovisc |
| Scilex Pharmaceuticals INC. | $59.93 | 2019 | |
| Medtronic, INC. | $58.22 | 2021-2025 | Inceptiv |
| Allergan, INC. | $58.12 | 2019-2020 | |
| Assertio Therapeutics, INC. | $53.10 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $44.73 | 2025 | Iovera, Zilretta |
| Pacira Therapeutics, INC. | $35.57 | 2020 | |
| Redhill Biopharma INC. | $34.18 | 2020-2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Forte Bio-Pharma LLC | $32.25 | 2023 | Prolate, Nalocet |
| Ferring Pharmaceuticals INC. | $23.03 | 2021 | |
| Atricure, INC. | $22.44 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $17.47 | 2023 | Uzedy |
| Almatica Pharma LLC | $15.50 | 2023 | Gralise |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Jan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.